Mr. Speaker, I would say to my colleague that this is highly offensive. Since the earliest days of the COVID-19 pandemic, we have focused on investing in made-in-Canada vaccine candidates across the nation and on increasing our domestic biomanufacturing capacity. Like Providence Therapeutics, every company that came forward was reviewed by the COVID-19 task force, which is made up of leading scientific and industry experts. In fact, we have invested nearly $10 million in Providence Therapeutics projects and I will continue to engage with the CEO, as I have done in the past.
In the House of Commons on May 4th, 2021. See this statement in context.